33
Participants
Start Date
January 31, 2011
Primary Completion Date
July 31, 2012
Study Completion Date
November 30, 2013
NP2
NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
Placebo
The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
Center for Clinical Research, Winston-Salem
Better Health Clinical Research Inc, Newnan
Advanced Pharma CR, Miami
Signal Point Clinical research Center, Middletown
Global Scientific Innovations, Evansville
Montana Cancer Institute Foundation, Missoula
Christie Clinic, Champaign
Medical Therapy and Research, San Antonio
HOPE Research Institute, Phoenix
Arizona Clinical Research Center, Tucson
White Memorial Medical Center, Los Angeles
TriWest Research Associates, La Mesa
Compassionate Cancer Care Medical Group, Inc., Corona
Cancer Care Associates, Fresno
Hematology Oncology Associates, Oakland
Pain Research of Oregon, Eugene
Medical Oncology Associates, Spokane
Hematology Oncology Associatesof Rhode Island, Cranston
Collaborators (1)
Paragon Biomedical
INDUSTRY
invivodata, Inc.
INDUSTRY
Diamyd Inc
INDUSTRY